ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA Kit

Erba Mannheim (London, England) has launched the ErbaLisa COVID-19 IgM ELISA kit for the detection of IgM antibodies to SARS-CoV-2 in response to the ongoing COVID-19 pandemic.

The ready-to-use ELISA kits allows for the qualitative and semi-quantitative detection of IgG/M antibodies to SARS-CoV-2 in human serum. Since IgM antibodies are produced first and detectable during disease onset, using the new assay in combination with Erba's existing ErbaLisa COVID-19 IgG ELISA can detect both early and late phases of the immune response.

Erba's solid phase assays use proven technology, and total incubation time is 50 minutes at room temperature with a simple one step serum dilution. ErbaLisa COVID-19 assays are built for superior performance and reliable interpretation of results. With full CE certification, the reliable and automation-friendly COVID-19 ELISA kits are now available through Erba's global distribution network, including in the US.

"We are working tirelessly to offer more options to clinicians and laboratories with which to gain an advantage in responding to this unprecedented global health crisis," said Nikhil Vazirani, MD of Erba Mannheim.